cyclofenil
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 2, 2023 (NCT05837156)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorMODULATOR
Estrogen receptor modulator
Cyclofenil is a weak non-steroidal oestrogen which has been used to induce ovulation, and more recently to treat systemic sclerosis. It is metabolized in rats, rabbits and man to cyclofenil diphenol (bis(p-hydroxyphenyl)cyclohexylidenemethane). Both of them bind to oestrogen receptors, although with a rather lower affinity than 17 beta-oestradiol.
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)Oc1ccc(C(=C2CCCCC2)c2ccc(OC(C)=O)cc2)cc1- Mol. weight
- 364.44 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL141305 ↗
Also known as
- cyclofenil
- cyclofenil
- cyclofenil
- cyclofenil
- cyclofenil
- cyclofenil
- cyclofenil
- cyclofenyl
- cyclopenil
- cyclophenil
- cyclophenyl
- f-6066
- f-6066
- fertodur
- ici-48213
- ici-48213
- neoclym
- neoclym
- ondogyne
- rehibin
- rehibin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05837156 | Phase 1 | Aug 2, 2023 | Sichuan University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1